Prime Medicine, Inc.2024财年实现净利润-1.96亿美元，同比增加1.01%

市场透视2025-03-09

3月9日，Prime Medicine, Inc.（PRME.US）公布财报，公告显示公司2024财年净利润为-1.96亿美元，同比增加1.01%；其中营业收入为2.98百万美元，每股基本收益为-1.65美元。从资产负债表来看，Prime Medicine, Inc.（PRME.US）总负债3.37亿美元，其中短期债务3.61百万美元，资产负债比为1.46，流动比率为0.06。机构评级：截至...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2518996447?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-09 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2518996447","market":"us","top_or_hot":-1,"title":"Prime Medicine, Inc.2024财年实现净利润-1.96亿美元，同比增加1.01%","media":"市场透视","content":"<div>\n<p>3月9日，Prime Medicine, Inc.（PRME.US）公布财报，公告显示公司2024财年净利润为-1.96亿美元，同比增加1.01%；其中营业收入为2.98百万美元，每股基本收益为-1.65美元。从资产负债表来看，Prime Medicine, Inc.（PRME.US）总负债3.37亿美元，其中短期债务3.61百万美元，资产负债比为1.46，流动比率为0.06。机构评级：截至...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000212abef97d9&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prime Medicine, Inc.2024财年实现净利润-1.96亿美元，同比增加1.01%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrime Medicine, Inc.2024财年实现净利润-1.96亿美元，同比增加1.01%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-09 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000212abef97d9&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月9日，Prime Medicine, Inc.（PRME.US）公布财报，公告显示公司2024财年净利润为-1.96亿美元，同比增加1.01%；其中营业收入为2.98百万美元，每股基本收益为-1.65美元。从资产负债表来看，Prime Medicine, Inc.（PRME.US）总负债3.37亿美元，其中短期债务3.61百万美元，资产负债比为1.46，流动比率为0.06。机构评级：截至...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000212abef97d9&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRME","symbol_name":"Prime Medicine, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000212abef97d9&s=b","article_id":"2518996447","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000212abef97d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2518996447","pubTimestamp":1741449656,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月9日，Prime Medicine, Inc.公布财报，公告显示公司2024财年净利润为-1.96亿美元，同比增加1.01%；其中营业收入为2.98百万美元，每股基本收益为-1.65美元。从资产负债表来看，Prime Medicine, Inc.总负债3.37亿美元，其中短期债务3.61百万美元，资产负债比为1.46，流动比率为0.06。机构评级：截至2025年3月9日，当前有10家机构对Prime Medicine, Inc.目标价做出预测，其中目标均价为12.90美元，其中最低目标价为6.00美元，最高目标价为19.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"PRME":"Prime Medicine, Inc."},"translate_title":"Prime Medicine, Inc. achieved net income of-$196 million in fiscal 2024, up 1.01% year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRME":1},"content_text":"3月9日，Prime Medicine, Inc.（PRME.US）公布财报，公告显示公司2024财年净利润为-1.96亿美元，同比增加1.01%；其中营业收入为2.98百万美元，每股基本收益为-1.65美元。从资产负债表来看，Prime Medicine, Inc.（PRME.US）总负债3.37亿美元，其中短期债务3.61百万美元，资产负债比为1.46，流动比率为0.06。机构评级：截至2025年3月9日，当前有10家机构对Prime Medicine, Inc.目标价做出预测，其中目标均价为12.90美元，其中最低目标价为6.00美元，最高目标价为19.00美元。公司简介：Prime Medicine Inc 是一家生物技术公司，致力于通过部署基因编辑技术 Prime Editing 提供基因疗法来治疗疾病。 Prime Editing技术是一种可以通过搜索和替换来恢复基因组中正常遗传功能，可以治疗具有高度未满足医疗需求的广泛疾病和高效广泛的基因编辑技术的下一代技术。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518996447","isCrawlerRequest":true}